When vaccines fall short in offering relevant immune protection in the Immunocompromised, what really works? When such suboptimal immune protection wanes a lot faster in comparison to that immunocompetent individuals, is there a better option?
“Ready-made”, sustainable Immune Protection perhaps?
Well that’s exactly what Evusheld ® – drugmaker AstraZeneca’s “New Kid on the Block” in the long-acting monoclonal antibody drug combo can potentially offer.
Continue reading “Evusheld ® : “Readymade” Immune Protection against COVID-19 in Immunocompromised”
